Alpine Immune Sciences, Inc.
ALPNDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Povetacicept | Phase 3 | Lupus Nephritis | - | - |
ALPN-101 | Phase 2 | Systemic Lupus Erythematosus | - | - |
Lupus Nephritis
1 drug in this indication
Systemic Lupus Erythematosus
1 drug in this indication
Immunoglobulin A Nephropathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Alpine Immune Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Alpine Immune Sciences, Inc.'s (ALPN) pipeline across Phase 3, Phase 2. Its lead program is Povetacicept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alpine Immune Sciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Alpine Immune Sciences, Inc. (ALPN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALPN biotech catalysts?→
Add ALPN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alpine Immune Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.